FlowOx SIGNED
Novel treatment for peripheral arterial disease
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0FlowOx project word cloud
Explore the words cloud of the FlowOx project. It provides you a very rough idea of what is the project "FlowOx" about.
Project "FlowOx" data sheet
The following table provides information about the project.
| Coordinator |
OTIVIO AS
Organization address contact info |
| Coordinator Country | Norway [NO] |
| Project website | https://www.otivio.com/eu |
| Total cost | 2˙747˙678 € |
| EC max contribution | 2˙080˙500 € (76%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2. (PRIORITY 'Industrial leadership') |
| Code Call | H2020-FTIPilot-2016-1 |
| Funding Scheme | IA |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-12-01 to 2019-11-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | OTIVIO AS | NO (OSLO) | coordinator | 876˙000.00 |
| 2 | INNOKAS MEDICAL OY | FI (KEMPELE) | participant | 680˙750.00 |
| 3 | THE UNIVERSITY OF SALFORD | UK (SALFORD) | participant | 375˙000.00 |
| 4 | BANGOR UNIVERSITY | UK (BANGOR) | participant | 148˙750.00 |
Map
Project objective
Peripheral Arterial Disease (PAD) is caused by the deposition of fatty material on the inner walls of peripheral arteries causing reducing perfusion and local nutrition to the muscles and skin. The condition affect 202 million people globally and is increasing at a rate of 20% per annum due to an aging population and epidemic growth of diabetes. The social costs amounts to $210 - 380 billion per annum. Behavioural changes such as smoking cessation, healthy nutrition and exercise is recommended to reduce impact and risk. When the condition worsens, patients ability to walk and exercise is reduced. When disease progress to critical limb ischemia (unbearable pain and chronic wounds), the patients follow a trajectory towards costly vascular surgery or amputation. FlowOx targets the gap in care with a patented, cost effective and clinically promising home treatment solution. In order to secure the successful introduction of FlowOx into the market by 2020, resources are required to fill the following gaps in innovation:1) strong clinical evidence of efficacy 2) health economic assessment 3) design for large scale manufacturing and 4) a validated commercial model Germany, UK and Scandinavia. These 4 challenges will be addressed in the FlowOx project over a 30-month period. The Fast Track to Innovation Pilot program was selected to support a resource demanding and technically challenging stage of the product roadmap. The support enables Otivio to join forces with a medical device manufacturer, Innokas Medical, Finland, and UK based Univ. of Salford and Univ. of Bangor with extensive experience in clinical and health economic studies. The FlowOx project enables Otivio and Innokas to enter the world-wide PAD market, gaining a strong market positon with a home care device for PAD treatment and expected sales of over €220 million within 5 years of launch.
Deliverables
| Project Website | Websites, patent fillings, videos etc. | 2020-03-23 19:00:21 |
| CE mark | Documents, reports | 2020-03-23 19:00:18 |
Take a look to the deliverables list in detail: detailed list of FlowOx deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Øyvind Heiberg Sundby, Ingebjørg Irgens, Lars Øivind Høiseth, Iacob Mathiesen, Eivind Lundgaard, Hanne Haugland, Harald Weedon-Fekjær, Jon O. Sundhagen, Gunnar Sandbæk, Jonny Hisdal Intermittent mild negative pressure applied to the lower limb in patients with spinal cord injury and chronic lower limb ulcers: a crossover pilot study published pages: 372-381, ISSN: 1362-4393, DOI: 10.1038/s41393-018-0080-4 |
Spinal Cord 56/4 | 2019-07-18 |
| 2017 |
Øyvind Heiberg Sundby, Lars Øivind Høiseth, Iacob Mathiesen, Harald Weedon-Fekjær, Jon O. Sundhagen, Jonny Hisdal The acute effects of lower limb intermittent negative pressure on foot macro- and microcirculation in patients with peripheral arterial disease published pages: e0179001, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0179001 |
PLOS ONE 12/6 | 2019-07-18 |
| 2016 |
Øyvind H. Sundby, Lars Ø. Høiseth, Iacob Mathiesen, Jørgen J. Jørgensen, Jon O. Sundhagen, Jonny Hisdal The effects of intermittent negative pressure on the lower extremities\' peripheral circulation and wound healing in four patients with lower limb ischemia and hard-to-heal leg ulcers: a case report published pages: e12998, ISSN: 2051-817X, DOI: 10.14814/phy2.12998 |
Physiological Reports 4/20 | 2019-07-18 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FLOWOX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FLOWOX" are provided by the European Opendata Portal: CORDIS opendata.